 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 GLOBE NEWSWIRE -- ERYTECH Pharma Nasdaq Euronext: ERYP, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer. 